Lilly Stockpiles Orforglipron Before FDA Review, Buys Orna Therapeutics for $2.4B
Eli Lilly has built substantial inventory of its oral GLP-1 candidate orforglipron in preparation for a pending FDA review, signaling readiness for rapid market launch. The company has also agreed to acquire Orna Therapeutics for $2.4 billion to add circular RNA-based gene therapy platform and clinical-stage ORN-252 to its pipeline.
1. Inventory Build of Orforglipron
Eli Lilly has ramped production of its oral GLP-1 candidate, orforglipron, building substantial inventory ahead of the drug’s pending FDA review. Manufacturing teams have secured initial batches to ensure minimal supply constraints at launch and to meet anticipated patient demand.
2. FDA Review Timeline and Launch Plans
The FDA review of orforglipron is expected in the coming months, with advisory committee feedback guiding final approval. Lilly aims for an immediate market rollout upon clearance, targeting physicians and patients seeking an oral obesity treatment.
3. Orna Therapeutics Acquisition Details
Lilly agreed to acquire Orna Therapeutics for $2.4 billion to integrate a circular RNA-based gene therapy platform. The deal adds Orna’s lead candidate, ORN-252, which leverages in vivo CAR-T technology and prepares for human trials in autoimmune diseases.
4. Pipeline Diversification and Growth Implications
These moves strengthen Lilly’s franchise beyond its tirzepatide GLP-1 drug by combining near-term launch potential with long-term gene therapy assets. Investors can expect broadened revenue streams and enhanced R&D capabilities.